Novel treatment to reduce the symptoms of influenza
Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of debilitating symptoms associated with influenza and 'influenza-like-illness' (ILI) by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need. Gemmus Pharma closes on Series A Funding to develop superior flu drug. Read more. Gemmus adds life sciences industry experts to Board of Directors. Read more.
Unlike antiviral therapies that focus on decreasing the production or release of viral particles, scientists at Gemmus are developing a drug that decreases the severity of the symptoms by modulating the release of pro-inflammatory cytokines.
Our lead candidate, GP1001, is an agonist of a G-protein coupled receptor (GPCR) which is expressed on human white blood cells. GP1001 has an extensive clinical safety record and it has been repurposed for the treatment of influenza infections.
The market for influenza therapies is over $1 billion worldwide per year and is expected to increase. There is a clear unmet need for treatments which are not susceptible to the rapid development of viral resistance and can reduce the severity of symptoms anytime during the disease.